The company was founded in 2017 to develop autologous and allogenic CAR T-cell therapy approaches. Since then, the company has developed two platforms -- FasTCAR and TruUCAR.

With the FasTCAR platform, Gracell is able to deliver younger, less exhausted T cells for autologous cell therapies that can be manufacturered within 22-36 hours. The company's lead FasTCAR candidate is GC012F, which is being evaluated in a phase I clinical trial in China for the treatment of relapsed or refractory multiple myeloma.

The TruUCAR T cells can be derived from nonhuman leukocyte antigen-matched healthy donors to generate allogenic CAR T-cell therapies that are available off-the-shelf at a lower cost for a broad patient base. The company's lead TruUCAR candidate, GC027, is being studied in a phase I clinical trial in China for the treatment of relapsed or refractory T-cell acute lymphoblastic leukemia.

Precigen nabs FDA nod for manufacturing UltraCAR-T therapies
Precigen has been granted clearance by the U.S. Food and Drug Administration (FDA) for its UltraPorator system. The system also had a successful technology...

Glycostem gets orphan drug nod for multiple myeloma cell therapy
Glycostem Therapeutics has received orphan drug designation by the U.S. Food and Drug Administration for its off-the-shelf natural killer cell product...

Bispecific CAR T therapy advances to a phase II trial
A new cancer treatment called double chimeric antigen receptor (CAR) T therapy for relapsed/refractory B-cell non-Hodgkin lymphoma has advanced to a phase...

CARsgen nabs orphan drug designation for anti-claudin18.2 CAR T therapy
CARsgen Therapeutics has been granted orphan drug designation by the U.S. Food and Drug Administration for CT041, a humanized anti-claudin18.2 autologous...